Axsome Therapeutics on Monday reported data for two Phase 3 studies in Alzheimer’s-related agitation, saying one trial succeeded while the…
Author: Max Gelman
Bristol Myers Squibb’s bet on TYK2 continued to pay off Monday, as Sotyktu passed two more Phase 3 tests in…
The FDA on Friday issued two simultaneous cystic fibrosis approvals for Vertex Pharmaceuticals but included high-level safety warnings for both.…
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday…
Applied Therapeutics is making changes to its leadership less than a month after the FDA rejected its rare disease drug.…
UCB and Novartis ended development on the lead program in their partnership after reporting a Phase 2a failure in Parkinson’s…
SAN DIEGO — New and experimental gene therapies made with blood stem cells rely on the same grueling, decades-old methods…
SAN DIEGO — Some of the biggest names in BTK inhibitors presented updated datasets at the American Society of Hematology…
SAN DIEGO — As researchers explore more potential benefits of GLP-1 medicines, a new retrospective study is suggesting the drug…
SAN DIEGO — AstraZeneca is getting ready to step on the gas in the world of bispecific T cell engagers.…